Monash research drives launch of new biotech targeting genetic kidney disease
xCystence Bio closes a syndicated pre-seed round backed by the Monash Ventures Pre-Seed Fund, Breakthrough Victoria, Uniseed and BioCurate.
CUREator backs Monash biotech to advance new therapeutics for polycystic kidney disease
CUREator top-up grant brings its total funding for xCystence Bio to A$750,000, advancing the programme towards preclinical proof of concept.